TY - JOUR
T1 - Focused update
T2 - Guidelines of care for the management of actinic keratosis
AU - Eisen, Daniel B.
AU - Dellavalle, Robert P.
AU - Frazer-Green, Lindsy
AU - Schlesinger, Todd E.
AU - Shive, Melissa
AU - Wu, Peggy A.
N1 - Publisher Copyright:
© 2022 American Academy of Dermatology, Inc.
PY - 2022/8
Y1 - 2022/8
N2 - Background: Actinic keratoses (AKs) are rough scaly patches that arise on chronically UV-exposed skin and can progress to keratinocyte carcinoma. Objective: In 2021, the American Academy of Dermatology published guidelines to assist in clinical decision-making for the management of AK. The purpose of this focused guideline update is to incorporate recently available evidence on the use of topical tirbanibulin to treat AK. Methods: A multidisciplinary work group conducted a systematic review to evaluate data on the use of tirbanibulin for AK and applied the Grading of Recommendations, Assessment, Development, and Evaluation approach for assessing the certainty of the evidence and formulating and grading a clinical recommendation. The graded recommendation was voted on to achieve consensus. Results: Two trials were identified, and analysis of the evidence resulted in 1 recommendation. Limitations: This analysis is based on the best available evidence at the time it was conducted. Long-term efficacy and safety data are not currently available. Conclusions: A strong recommendation for the use of topical tirbanibulin to join the currently recommended list of topical therapies for AK was made on the basis of the available evidence.
AB - Background: Actinic keratoses (AKs) are rough scaly patches that arise on chronically UV-exposed skin and can progress to keratinocyte carcinoma. Objective: In 2021, the American Academy of Dermatology published guidelines to assist in clinical decision-making for the management of AK. The purpose of this focused guideline update is to incorporate recently available evidence on the use of topical tirbanibulin to treat AK. Methods: A multidisciplinary work group conducted a systematic review to evaluate data on the use of tirbanibulin for AK and applied the Grading of Recommendations, Assessment, Development, and Evaluation approach for assessing the certainty of the evidence and formulating and grading a clinical recommendation. The graded recommendation was voted on to achieve consensus. Results: Two trials were identified, and analysis of the evidence resulted in 1 recommendation. Limitations: This analysis is based on the best available evidence at the time it was conducted. Long-term efficacy and safety data are not currently available. Conclusions: A strong recommendation for the use of topical tirbanibulin to join the currently recommended list of topical therapies for AK was made on the basis of the available evidence.
KW - actinic keratosis
KW - actinic keratosis guidelines
KW - clinical guidelines for actinic keratosis
KW - tirbanibulin
KW - topical agents
UR - http://www.scopus.com/inward/record.url?scp=85131514610&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85131514610&partnerID=8YFLogxK
U2 - 10.1016/j.jaad.2022.04.013
DO - 10.1016/j.jaad.2022.04.013
M3 - Article
C2 - 35439607
AN - SCOPUS:85131514610
SN - 0190-9622
VL - 87
SP - 373-374.e5
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
IS - 2
ER -